Supplement production and support for small-lot, high-mix OEM manufacturing
First written in FY2016. 14 of 26 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026ReframedAnnual report
「In the fiscal year ending March 2026, as part of the reorganisation of its production sites, the company suspended operations at and sold the Komoro Plant, aiming to improve production efficiency and reduce fixed costs while also working to reduce its environmental impact.」
The disclosure shifted from the previous focus on expanding and establishing the manufacturing base to an emphasis on reorganising production sites, suspending operations at and selling the Komoro Plant, and reducing fixed costs. - FY2024-Q3RestatedAnnual report
「There were no material changes to the management policies, management strategies or other matters established by the Group during the cumulative consolidated third quarter under review.」
The company states that there have been no material changes to its existing manufacturing strategy, including supplement production and its ability to handle small-lot, high-mix OEM manufacturing. - FY2023SoftenedAnnual report
「There are no plans to establish any major new facilities.」
The company states that, as of the end of the current consolidated fiscal year, there were no material plans to install new equipment for the manufacturing base, including supplement production and small-lot, high-mix OEM manufacturing. - FY2023-Q1RestatedAnnual report
「There were no significant changes during the first quarter cumulative consolidated period to the management policies, management strategies or other matters established by our group.」
The company states that there have been no material changes to its existing manufacturing strategy, including supplement production and its ability to handle small-lot, high-mix OEM manufacturing. - FY2022-Q3RestatedAnnual report
「There were no material changes to the management policies, management strategies or other matters established by the Group during the cumulative consolidated third quarter under review.」
The company states that there have been no material changes to its existing manufacturing strategy, including supplement production and its ability to handle small-lot, high-mix OEM manufacturing. - FY2022-Q1RestatedAnnual report
「There were no significant changes during the first quarter cumulative consolidated period to the management policies, management strategies or other matters established by our group.」
The company states that there have been no material changes to its existing manufacturing strategy, including supplement production and its ability to handle small-lot, high-mix OEM manufacturing. - FY2021RestatedAnnual report
「During the consolidated fiscal year, total investment amounted to ¥881.656 million. The main investments were ¥796.256 million in property, plant and equipment, including buildings and machinery at the New Komoro Plant, and ¥85.400 million in intangible assets, including logistics system software.」
Investment in the manufacturing base, including the New Komoro Plant, is continuing. During the current fiscal year, ¥796.256 million was invested in buildings, machinery and other assets at the New Komoro Plant. - FY2021-Q3AdvancedAnnual report
「Fixed assets increased by ¥221.338 million from the end of the previous fiscal year to ¥6,164.500 million. This was mainly due to completion of construction of the new Komoro Plant and an increase in deferred tax assets.」
The completion of construction of the New Komoro Plant is disclosed, indicating that a specific milestone has been reached in developing the manufacturing base, including supplement production. - FY2021-Q2AdvancedAnnual report
「This was mainly attributable to ¥488.559 million in expenditures for the acquisition of property, plant and equipment related to construction costs and other expenses for the new Komoro Plant, and ¥84.158 million in expenditures for the acquisition of intangible assets consisting of software for logistics systems and other systems.」
¥488.559 million in expenditures for the acquisition of property, plant and equipment related to construction of the New Komoro Plant was recorded, indicating progress in developing the manufacturing base, including supplement production. - FY2021-Q1RestatedAnnual report
「There were no significant changes during the first quarter cumulative consolidated period to the management policies, management strategies or other matters established by our group.」
The company states that there have been no material changes to its existing manufacturing strategy, including supplement production and its ability to handle small-lot, high-mix OEM manufacturing. - FY2020AdvancedAnnual report
「Construction contract for the New Komoro Plant ¥644.000 million December 2020」
A construction contract was signed for the New Komoro Plant, with a contract price of ¥644.000 million and a scheduled completion date of December 2020. Property, plant and equipment investment for the current fiscal year totaled ¥700.212 million, including investment related to the New Komoro Plant. - FY2020-Q3AdvancedAnnual report
「Fixed assets increased by ¥307.523 million from the end of the previous fiscal year to ¥5,881.847 million. This was mainly due to an increase in construction in progress resulting from payments for part of the construction costs and other expenses related to the new Komoro Plant, and an increase in software for logistics systems and other systems.」
The company states that construction in progress increased as a result of payments for part of the construction costs and other expenses related to the New Komoro Plant, indicating progress in developing the manufacturing base. - FY2020-Q2AdvancedAnnual report
「This was mainly attributable to ¥299.580 million in expenditures for the acquisition of property, plant and equipment related to construction costs and other expenses for the new Komoro Plant, and ¥78.731 million in expenditures for the acquisition of intangible assets consisting of software for logistics systems and other systems.」
¥299.580 million in expenditures for the acquisition of property, plant and equipment related to construction of the New Komoro Plant was recorded. In addition, a construction contract for the New Komoro Plant was signed on 24 September 2019, with a contract price of ¥644.000 million and a scheduled completion date of 29 September 2020. - FY2020-Q1RestatedAnnual report
「There were no significant changes during the first quarter cumulative consolidated period to the management policies, management strategies or other matters established by our group.」
The company states that there have been no material changes to its existing manufacturing strategy, including supplement production and its ability to handle small-lot, high-mix OEM manufacturing. - FY2019AdvancedAnnual report
「This was mainly due to ¥302.366 million in expenditures for the acquisition of property, plant and equipment through expansions of research and development facilities, plant facilities and other projects, and ¥170.472 million in expenditures for the acquisition of intangible assets, including software for new systems.」
¥302.366 million was invested in expansions of research and development facilities, plant facilities and other projects, strengthening the production and research and development base. - FY2019-Q3RestatedAnnual report
「There were no material changes to the management policies, management strategies or other matters established by the Group during the cumulative consolidated third quarter under review.」
The company states that there have been no material changes to its existing manufacturing strategy, including supplement production and its ability to handle small-lot, high-mix OEM manufacturing. - FY2019-Q2AdvancedAnnual report
「This was primarily attributable to ¥180.729 million in expenditures for the acquisition of tangible fixed assets, including expansions of research and development facilities and factory equipment, and ¥98.780 million in expenditures for the acquisition of intangible fixed assets consisting of software for new systems and other purposes.」
¥180.729 million was spent on the acquisition of property, plant and equipment through expansions of plant facilities and other projects, indicating concrete progress in investment to expand the manufacturing base. - FY2019-Q1RestatedAnnual report
「There were no significant changes during the first quarter cumulative consolidated period to the management policies, management strategies or other matters established by our group.」
The company states that there have been no material changes to its existing manufacturing strategy, including supplement production and its ability to handle small-lot, high-mix OEM manufacturing. - FY2018AdvancedAnnual report
「The principal capital expenditures planned for the next consolidated fiscal year are expansions in both manufacturing and logistics, to be funded by internal funds and long-term borrowings from financial institutions.」
The company identifies expansions in both manufacturing and logistics as major capital expenditures for the next fiscal year. In the current fiscal year, it invested ¥715.580 million in property, plant and equipment out of total capital expenditures of ¥976.603 million. - FY2018-Q3RestatedAnnual report
「There were no material changes to the management policies, management strategies or other matters established by the Group during the cumulative consolidated third quarter under review.」
The company states that there have been no material changes to its existing management strategy, including supplement production and its ability to handle small-lot, high-mix OEM manufacturing. - FY2018-Q2RestatedAnnual report
「There were no significant changes during the second quarter cumulative consolidated period to the management policies, management strategies or other matters established by our group.」
The company states that there have been no material changes to its existing management strategy, including supplement production and its ability to handle small-lot, high-mix OEM manufacturing. - FY2018-Q1RestatedAnnual report
「There were no significant changes during the first quarter cumulative consolidated period to the management policies, management strategies or other matters established by our group.」
The company states that there have been no material changes to its existing management strategy, including supplement production and its ability to handle small-lot, high-mix OEM manufacturing. - FY2017-Q3RestatedAnnual report
「At ハーバー株式会社's North Genesis Plant, we are expanding manufacturing capabilities over the medium to long term by undertaking full-scale production of supplements, candy and other products, while the company's Narita Plant handles OEM contract manufacturing for small-lot, high-mix production.」
The company reiterates its plan to strengthen manufacturing by dividing functions between the North Genesis Plant and the Narita Plant. - FY2017-Q2AdvancedAnnual report
「At ハーバー株式会社's North Genesis Plant, we are expanding manufacturing capabilities over the medium to long term by undertaking full-scale production of supplements, candy and other products, while the company's Narita Plant handles OEM contract manufacturing for small-lot, high-mix production.」
¥146.873 million was spent on the acquisition of property, plant and equipment through plant expansions and other projects, and machinery, equipment and vehicles also increased. The disclosure describes concrete progress in equipment acquisition to strengthen manufacturing by dividing functions between the North Genesis Plant and the Narita Plant. - FY2017-Q1RestatedAnnual report
「At ハーバー株式会社's North Genesis Plant, we are expanding manufacturing capabilities over the medium to long term by undertaking full-scale production of supplements, candy and other products, while the company's Narita Plant handles OEM contract manufacturing for small-lot, high-mix production.」
The company reiterates its plan to strengthen manufacturing by dividing functions between the North Genesis Plant and the Narita Plant. - FY2016First statedAnnual report
「At ハーバー株式会社's North Genesis Plant, we are expanding manufacturing capabilities over the medium to long term by undertaking full-scale production of supplements, candy and other products, while the company's Narita Plant handles OEM contract manufacturing for small-lot, high-mix production.」
The policy is to strengthen manufacturing capacity by assigning different manufacturing functions to the North Genesis Plant and the Narita Plant.